This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Volpara Health Technologies 配当と自社株買い

配当金基準チェック /06

Volpara Health Technologies配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.3%

バイバック利回り

総株主利回り	-0.3%
将来の配当利回り	0%
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

What Volpara Health Technologies Limited's (ASX:VHT) 52% Share Price Gain Is Not Telling You

Dec 19

We're Hopeful That Volpara Health Technologies (ASX:VHT) Will Use Its Cash Wisely

Mar 06

Calculating The Intrinsic Value Of Volpara Health Technologies Limited (ASX:VHT)

Jun 03

Does Volpara Health Technologies (ASX:VHT) Have A Healthy Balance Sheet?

Mar 24

Volpara Health Technologies (ASX:VHT) Shareholders Booked A 93% Gain In The Last Three Years

Jan 28

Volpara Health Technologies (ASX:VHT) Is Using Debt Safely

Dec 24

Here's What We Think About Volpara Health Technologies' (ASX:VHT) CEO Pay

Nov 19

決済の安定と成長

配当データの取得

安定した配当: VHTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: VHTの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Volpara Health Technologies 配当利回り対市場

VHT 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (VHT)	n/a
市場下位25% (AU)	2.6%
市場トップ25% (AU)	6.1%
業界平均 (Healthcare Services)	1.0%
アナリスト予想 (VHT) (最長3年)	0%

注目すべき配当: VHTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: VHTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: VHTの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: VHTが配当金を報告していないため、配当金の持続可能性を計算できません。

This company listing is no longer active

Volpara Health Technologies 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Volpara Health Technologies Limited Appoints Craig Hadfield Joins as Chief Financial Officer

Price target decreased by 7.7% to AU$0.92

Volpara Health Technologies Limited Launches MQSA Compliance Software at the Society for Breast Imaging Symposium

Price target decreased by 13% to AU$1.00

What Volpara Health Technologies Limited's (ASX:VHT) 52% Share Price Gain Is Not Telling You

Lunit Inc. (KOSDAQ:A328130) agreed to acquire Volpara Health Technologies Limited (ASX:VHT) from Harbour Asset Management Limited and others for AUD300 million.

Price target increased by 14% to AU$1.15

First half 2024 earnings released: NZ$0.017 loss per share (vs NZ$0.021 loss in 1H 2023)

Price target decreased by 16% to AU$1.01

Forecast breakeven date pushed back to 2026

New major risk - Revenue and earnings growth

Volpara Health Technologies Limited to Report Q2, 2024 Results on Oct 17, 2023

An Unknown buyer acquired 4% stake in Reveal DX fromVolpara Health Technologies Limited (ASX:VHT).

Volpara Health Technologies Limited, Annual General Meeting, Aug 17, 2023

Volpara Health Technologies Limited to Report Q1, 2024 Results on Jul 21, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 137%, revenue upgraded

We're Hopeful That Volpara Health Technologies (ASX:VHT) Will Use Its Cash Wisely

Volpara Health Technologies Limited Appoints Mark Bouw as Independent, Non-Executive Director

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: NZ$0.02 loss per share (vs NZ$0.034 loss in 1H 2022)

Volpara Health Technologies Limited Provides Revenue Guidance for the Full Year 2023

Forecast breakeven date moved forward to 2024

Consensus estimates of losses per share improve by 14%

Forecast breakeven date moved forward to 2024

Volpara Health Technologies Limited Appoints Fred Struve as Joint Company Secretary

Forecast to breakeven in 2025

Volpara Health Technologies Limited Announces the Appointment of Teri Thomas as Managing Director

Volpara Health Launches Professional Services to Accelerate Success for High-Risk Cancer Programs

Forecast breakeven date pushed back to 2025

Key Executive recently bought AU$67k worth of stock

Now 23% undervalued after recent price drop

Price target decreased to AU$1.15

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Volpara Health Announces Chief Executive Officer Changes

No longer forecast to breakeven

Price target decreased to AU$1.62

No longer forecast to breakeven

First half 2022 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Price target increased to AU$2.00

Non-Executive Director Monica Saini has left the company

Price target decreased to AU$1.74

Volpara Grows Patent Collection with Recently Granted European Protection of Image Quantification

Insider recently sold AU$122k worth of stock

Calculating The Intrinsic Value Of Volpara Health Technologies Limited (ASX:VHT)

Consensus EPS estimates fall to -NZ$0.046

Forecast breakeven pushed back to 2024

Full year 2021 earnings released: NZ$0.07 loss per share (vs NZ$0.097 loss in FY 2020)

Price target decreased to AU$1.84

Price target increased to AU$1.99

Does Volpara Health Technologies (ASX:VHT) Have A Healthy Balance Sheet?

Volpara Health Technologies Signs Highest Value Contract to Date Via CRA Health

New 90-day low: AU$1.30

Volpara Health Technologies Limited (ASX:VHT) acquired CRA Health Services, Inc. for $22 million.

Price target raised to AU$1.81

New 90-day high: AU$1.54

Volpara Health Technologies (ASX:VHT) Shareholders Booked A 93% Gain In The Last Three Years

Volpara Health Technologies Limited to Report Q3, 2021 Results on Jan 28, 2021

Volpara Health Technologies (ASX:VHT) Is Using Debt Safely

Volpara Health Technologies Advises Major Customer Contract It Renewed and Extended in Second Quarter of Fiscal 2021 Is with the US Radiology Group

First half 2021 earnings released: NZ$0.036 loss per share

Here's What We Think About Volpara Health Technologies' (ASX:VHT) CEO Pay

Volpara Health Technologies Announces the Launch of BreastED

New 90-day high: AU$1.47

New 90-day low: AU$1.27

Volpara Health Technologies Limited to Report Q1, 2021 Results on Jul 28, 2020

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /06